Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.

Abstract

Treating patients with anthracycline- and taxane-pretreated metastatic breast cancer (MBC) represents a significant challenge to oncologists. The tumour-activated oral fluoropyrimidine, capecitabine, is the only treatment approved for these patients. Our study evaluated the efficacy, safety and impact on quality of life (QOL) of capecitabine in this setting. Patients (n=126) with anthracycline- and taxane-pretreated metastatic breast cancer received capecitabine 1250 mg/m(2) twice daily, days 1-14, followed by a 7-day rest period. Median time to progression was 4.9 months (95% Confidence Interval (CI): 4.0-6.4). Thirty-five patients (28%) achieved an objective response (95% CI: 20-36%), including five (4%) complete responses. Median overall survival was 15.2 months (95% CI: 13.5-19.6 months). Capecitabine demonstrated a favourable safety profile, with a low incidence of treatment-related grade 3/4 adverse events. The most common adverse events were hand-foot syndrome and gastrointestinal effects. QOL assessment showed that capecitabine treatment was associated with an increase in mean Global Health Score. Capecitabine is active, well tolerated and improves the QOL of patients with anthracycline- and taxane-pretreated metastatic breast cancer. Based on the consistently high activity demonstrated in clinical trials, capecitabine has become the reference treatment in this setting.

• Authors: P Fumoleau, R Largillier, C Clippe, V Dièras, H Orfeuvre, T Lesimple, S Culine, B Audhuy, D Serin, H Curé, E Vuillemin, J-F Morère, F Montestruc, Z Mouri, M Namer
• Journal: European journal of cancer (Oxford, England : 1990) (Eur J Cancer) Vol. 40 Issue 4 Pg. 536-42 (Mar 2004) ISSN: 0959-8049 [Print] England
• PMID: 14962720 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study)

Chemical References

• Anthracyclines
• Antimetabolites, Antineoplastic
• Bridged-Ring Compounds
• Taxoids
• Deoxycytidine
• taxane
• Capecitabine
• Fluorouracil

Topics

• Adult
• Aged
• Aged, 80 and over
• Anthracyclines (therapeutic use)
• Antimetabolites, Antineoplastic (therapeutic use)
• Breast Neoplasms (drug therapy)
• Bridged-Ring Compounds (therapeutic use)
• Capecitabine
• Deoxycytidine (analogs & derivatives, therapeutic use)
• Disease-Free Survival
• Drug Resistance, Neoplasm
• Female
• Fluorouracil (analogs & derivatives)
• Follow-Up Studies
• Humans
• Middle Aged
• Neoplasm Metastasis
• Quality of Life
• Taxoids (therapeutic use)
• Treatment Outcome